Welcome to our dedicated page for Varex Imaging SEC filings (Ticker: VREX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Varex Imaging Corporation filings document operating results, financing agreements, governance votes and material events for an X-ray imaging component manufacturer. Recent 8-K reports furnish preliminary quarterly and fiscal-year results, including segment disclosures for the Medical and Industrial businesses and product-demand commentary for CT, cargo systems and detectors.
The company’s regulatory filings also describe its Credit and Guaranty Agreement, secured term loan, revolving credit and delayed draw term loan facilities, subsidiary guarantees, covenants and senior secured note redemption. Governance filings record annual meeting voting results, director elections, auditor ratification, executive compensation votes and officer transition arrangements.
Varex Imaging Corp director Jay K. Kunkel received a grant of 12,331 Deferred Stock Units on February 12, 2026. The grant is recorded at a price of $0 per unit and is reported as directly owned.
Each Deferred Stock Unit converts into one share of Varex common stock. The units vest 100% on the earlier of one year from the grant date or the next annual stockholder meeting after the grant. Vested shares are delivered on the earlier of the third anniversary of the grant, a change in control, or Kunkel’s termination of service for any reason.
Varex Imaging Corp director Walter M. Rosebrough Jr. received a grant of 14,947 Deferred Stock Units on February 12, 2026. These units were awarded at a price of $0 as a form of equity compensation and are held as a derivative security.
Each Deferred Stock Unit converts into one share of Varex Imaging common stock. The units vest 100% on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, and the underlying shares will be delivered on the earlier of the third anniversary of the grant, a change in control, or the director’s termination of service.
Varex Imaging Corp director Christine A. Tsingos received an equity grant of 12,331 deferred stock units on February 12, 2026. The units were awarded at a price of $0 and are held directly. Each deferred stock unit converts into one share of Varex common stock.
The deferred stock units vest 100% on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders after the grant. Vested shares will be delivered to the director on the earlier of the third anniversary of the grant date, a change in control, or her termination of service.
Varex Imaging Corp director Timothy E. Guertin reported an award of deferred stock units. On February 12, 2026, he acquired 12,331 Deferred Stock Units at a price of $0, all held directly.
Each unit converts into one share of common stock. The units vest 100% on the earlier of the one-year anniversary of the grant date or the next annual stockholders’ meeting. Vested shares will be delivered on the earlier of the third anniversary of the grant date, a change in control, or Guertin’s termination of service.
Varex Imaging Corp director Jocelyn D. Chertoff received an equity award in the form of deferred stock units. On 02/12/2026, she was granted 12,331 Deferred Stock Units at a price of $0. Each unit converts into one share of common stock.
The Deferred Stock Units vest 100% on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders after the grant. Vested shares will be delivered to her on the earlier of the third anniversary of the grant date, a change in control, or her termination of service.
Varex Imaging Corporation reported higher revenue and a small profit for the quarter ended January 2, 2026. Net revenues rose to $209.6M from $199.8M, and net income attributable to Varex improved to $2.3M, or $0.05 per diluted share, compared with a small loss a year earlier.
Industrial revenue grew to $64.8M from $55.2M, while Medical revenue was essentially flat at about $144.8M. Operating income increased to $15.4M, but interest and other expense of $11.6M (including a $3.2M equity-method loss from dpiX Holding) limited bottom-line growth.
Cash flow from operating activities was a use of $16.1M, driven largely by a $30.1M inventory build to $328.0M. Cash and cash equivalents declined to $119.5M, while Senior Secured Notes outstanding remained at $368.0M. The $155.0M revolving credit facility was undrawn, with $154.8M available. After quarter-end, Varex committed about $7.3M over three years for new manufacturing equipment.
Varex Imaging Corporation reported a solid first quarter of fiscal 2026 with year-over-year growth and improved profitability. Revenue reached $209.6 million, up 5% from $199.8 million a year earlier, driven by a 17% year-over-year increase in Industrial segment revenue to $64.8 million, while Medical revenue was stable at $144.8 million.
GAAP net income attributable to Varex improved to $2.3 million, or $0.05 per diluted share, from a loss of $0.3 million, or $(0.01) per diluted share, in the prior-year quarter. Non-GAAP diluted net income per share increased to $0.19 from $0.10, and non-GAAP operating margin rose to 9.0%. Adjusted EBITDA grew to $28.5 million from $25.5 million.
Operating cash flow was a $16 million outflow, and cash, cash equivalents, and marketable securities declined to $125.6 million at quarter-end from $155.1 million at the end of fiscal 2025, primarily due to higher inventories. For the second quarter of fiscal 2026, the company expects revenue between $210 million and $225 million and non-GAAP net earnings per diluted share between $0.15 and $0.25.
Varex Imaging Corp director Jay K. Kunkel reported a routine equity award settlement. On February 9, 2026, he converted 8,483 Deferred Stock Units into 8,483 shares of common stock at a price of $0 per share, reflecting previously granted director compensation.
The Deferred Stock Units were granted on February 9, 2023, vested on February 8, 2024, and were delivered in common stock on the third anniversary of the grant date. Following this settlement, Kunkel directly holds 27,960 shares of Varex Imaging Corp common stock.
Varex Imaging Corp director Jocelyn D. Chertoff reported the conversion of 8,483 Deferred Stock Units into 8,483 shares of common stock on February 9, 2026, at an exercise price of $0 per unit.
The footnotes state these Deferred Stock Units were granted on February 9, 2023, vested on February 8, 2024, and were delivered in stock on the third anniversary of the grant date. Following this settlement, Chertoff directly holds 42,194 shares of Varex Imaging common stock and no remaining Deferred Stock Units from this grant.
Varex Imaging Corp director Walter M. Rosebrough Jr. reported the conversion of 10,339 Deferred Stock Units into an equal number of Varex common shares on February 9, 2026. These units were originally granted on February 9, 2023 and became deliverable on the third anniversary of the grant date.
After this settlement, Rosebrough directly beneficially owns 52,654 shares of common stock. The Form 4 shows a routine equity compensation event with no cash consideration, as both the derivative units and the resulting common shares are reported at a transaction price of $0 per share.